INTRODUCTION
Adjuvant cancer chemotherapy has long been the accepted strategy for the treatment of several types of malignant tumors, especially those involving metastases (1) . To enhance the efficacy of chemotherapy, multiple agents, longer and more intensive treatment, and combination therapy have been used. Although these modified approaches have resulted in improvements, the severity of side effects (2) and the gradual resistance developed by tumors during therapy (3) continue to hinder the efficacy of cancer chemotherapy. Consequently, more efficient delivery systems are needed to reduce the toxicity associated with cancer chemotherapy, while preserving the effectiveness of the respective chemotherapeutic agents.
In order to reduce the toxicity of chemotherapeutic agents, delivery vehicles including liposomes have been investigated (4, 5) . Some of the data emerging from these studies have shown that the efficacy of the drug delivery by liposomes was inversely related to the diameter of the particle (6) . However, even the smallest liposomes have a diameter five times larger than the average high density lipoprotein (HDL) particle, a hydrophobic lipid micelle core with surface components of phospholipid and apolipoproteins (7) .
Because the overall properties of HDL are consistent with a potentially superior hydrophobic drug transporter, we have undertaken the investigation of rHDL particles as delivery vehicles for cancer chemotherapeutic agents.
KEY RESEARCH ACCOMPLISHMENTS
This is a "Concept Award" report. Due to the limited funding, the accomplishments are correspondingly modest. Nevertheless, we are pleased to report numerous exciting findings, two poster presentations at national meetings and some extended funding for this project.
The following scientific accomplishments can be documented during the second year of this award.
1. Studies using mice were conducted to investigate the stability of the rHDL preparations in vivo. These studies show that about ten times of the amount of the anti-cancer drug (taxol) is present in the circulation when it is administered as part of the rHDL complex as compared to the free drug 2. A model compound, dilauroyl fluoresceine, has been developed for the investigation of drug delivery to tumors ,using lipoprotein vehicles 3. Results of uptake studies, using transformed cell lines expressing high levels of the SRB-1 receptor are consistent with our earlier findings, indicating an important role for this receptor in the biology of cancer cells and the uptake of anti-cancer drugs. using this meciianism may be able to overcome the tendencey of many cancer cells and tumors for drug resistance.
Studies in Progress:
We are currently investigating new agents that may be particularly effective against breast cancer cells and tumors when encapsulated into the rHDL complex.
REPORTABLE OUTCOMES
We have had an article published in "Anticancer Research" (see attached).
We presented our findings at the "ERA of Hope" meeting in September, 2002.
We presented our findings at the ASBMB meeting in San Diego in April 2003.
We have obtained additional pilot funding to continue this project from the Faculty Research Fund.
We have filed an application with the US Patent Office.
CONCLUSIONS
We have completed al the projected goals that were outlined for this project in the "Concept proposal". The next phase of our studies involves translational studies with animals that will require substantially higher level of funding. Accordingly, we have been submitting proposals to the DOD Breast Cancer Program, the National Institutes of Health and to the Susan G. Komen Breast Cancer Foundation. We are hopeful that these efforts will result in additional funding and the continuation of our work.
Regarding the overall potential impact of our research, we believe that it has unlimited potential. Accordingly, our research has wide applications in breast cancer chemotherapy because, in addition to taxol, many of the frequently employed drugs are poorly water soluble and their application would thus be substantially improved by the rHDL delivery system. In addition, because of the vast potential for targeting, via modifications of its protein or lipid components, the future application of the rHDL drug delivery system could revolutionize chemotherapy via tumor specific targeting and potentially overcoming drug resistance. The proposed approach has the additional potential to substantially improve the delivery of anticancer drugs to hormone resistant breast tumors and thus enhance the prognosis for the survival of breast cancer patients. Adjuvant cancer chemotherapy has long been the accepted strategy for the treatment of several types of malignant tumors, especially those involving metastases (1) . To enhance the efficacy of chemotherapy, multiple agents, longer and more intensive treatment, and combination therapy have been used. Although these modified approaches have resulted in improvements, the severity of side effects (2) and the gradual resistance developed by tumors during therapy (3) continue to hinder the efficacy of cancer chemotherapy. Consequently, more efficient delivery systems are needed to reduce the toxicity associated with cancer chemotherapy, while preserving the effectiveness of • the respective chemotherapeutic agents. ■ In order to reduce the toxicity of chemotherapeutic agents, delivery vehicles including liposomes have been investigated (4, 5) . Some of the data emerging from these studies have shown that the efficacy of the drug delivery by liposomes was inversely-related to the diameter of the particle (6). However, even the smallest liposomes have a diameter five-times larger than the average high density lipoprotein (HDL) particle, a hydrophobic lipid micelle with surface components of phospholipid and apolipoproteins (7^. Because the overall properties of HDL are consistent with a potentially superior hydrophobic drug transporter, we have undertaken the investigation of rHDL particles as delivery vehicles for cancer chemotherapeutic agents.
While preparations of reconstituted HDL were developed over thirty years ago (8) , this approach has been used primarily to characterize the physical and chemical properties of HDL (9) (10) (11) and to conduct metabolic studies (12) (13) . Trials aimed at a clinical application of HDL particles have been reported to relieve endotoxic shock (14) and to arrest or reverse atherosclerosis (15) . An application involving reconstituted HDL has been reported by Bijsterbosch and Van Berkel (16) who used lactosylated HDL to target delivery of antiviral drugs to liver tissue. Earlier studies also indicated that the proliferation of breast cancer cells and other adenocarcinoma cells (17) (18) (19) are dependent on the; uptake of HDL components. Thus an additional advantage of using HDL for delivering chemotherapeutic agents is the direct uptake of hydrophobic core components from HDL by Specific cell surface receptors, including those expressed by tumor cells (20, 21) .
The present study shows that a number of cultured human cancer cells are nearly as efficient as the model ovarian granulosa cells (HGL5) in the uptake of cholesteryl esters and taxol from the lipid core of recombinant HDL (rHDL) complexes, indicating that HDL may be used to solubilize otherwise very poorly water soluble (hydrophobic) therapeutic agents for injection into the systemic circulation. The TX containing rHDL fractions were isolated by density gradient ultracentrifugation as described previously (22) and dialyzed overnight against 4.3 mM Na2HP04.1.2 mM KH2P04,137 mM NaCl, 2.7 mM KCI, pH 7.4 at 4''C.
Materials and Methods

Preparation
Determination of rHDL componenls. Total cholesterol (Data Medical
Associates, Arlington TX, USA), free cholesterol and phospholipids (Wako Pure Chemical Industries Ltd), were determined by respective enzymatic reagent kits, using microtiterplate assays (22) . The concentration of cholcsteryl esters was obtained as the difference between total and free cholesterol values. Taxol was determined by immunoassay as described by Leu el al (23) . Protein determinations were carried out using Bradford reagent kits supplied by BioRad Laboratories.
Molecular weight determination. The molecular weight of the rHDL complex was determined by gel chromatography on 1.5X 80 cm AcA-34 (BioSepra.'Life Technologies Inc.) columns using apoferritin, alcohol dehydrogenase, serum albumin and ovalbumin as standards. The molecular weight of the rHDL complex was calculated based on the principles described by Ackers (24) . 
Monitoring of the uptake of core components from rHDL by cultured cells.
On the first day the cells were plated in 12-well plates (50,000 cells/well) in their respective media. On the next day, the monolayers were washed with PBS pH 7.4 and then incubated at 37°C for 2 hours with varying amounts of rHDL-^H-cholesteryl oleate and rHDL-Taxol ('''c -taxol) complexes in serum free media (KGM). Following the 2-hour incubation period, the cells were washed with PBS pH 7.4 and dissolved in 0.5M NaOH in preparation for scintillation counting.
Screening of cell cultures for taxol uptake. Radio-labeled '"c -taxol (Sigma) was incorporated into the rHDL particles along with the unlabeled taxol, as described above. The amount of TX taken up by the cells was monitored by scintillation counting. Taxol mass was computed from the specific radioactivities of the preparations that was earlier established by immunoassay (23) .
Assessment of the cell killing potential of the rHDLIdrug complexes.
The cytotoxic effect of the rHDUdrug preparations on cancer cells was assessed by sulforhodamine B (26). The assessment of TX toxicity was performed as follows. Cells grown to 80-90% confluency were detached from the flask by digesting with 0.25% Trypsin. The cells were subsequently washed from the flask with complete media and centrifuged for 5 minutes at lOOOg to pellet them. The cells were then resuspended in complete media and an aliquot was diluted 1:1 with Trypan Blue. The cells were counted and their viability determined as follows: the cells seeded in 96-well microtiter plates (at 3000 cells per Western-blot analysis. The cancer cells were grown until confluent, washed with PBS (pH 7.4) and scraped off the surface with 500^1 of buffer containing 50mM Tris-HCI, 150mM NaCl, 0.02% sodium azide, 1% Triton X-100, lOO^ig/ml PMSF and lug/ml aprotinin. The cells were subsequently boiled for 5 minutes and then centrifuged at 1,000 rpm for 10 minutes and the supernatant used for Western-blot analysis. Ten ug of protein was mixed with equal volume of sample buffer, boiled for 4 minutes, and applied to a SDS-PAGE gel (10%). The protein was transferred to nitrocellulose overnight at 4°C. Immunoreactive bands were detected with a polyclonal rabbit antiserum (Novus biologicals) raised against a peptide containing residues 496-509 from mouse SRB-1, known to react with the human SRB-1 analog, CLA-1. Horseradish peroxidase conjugated goat anti-rabbit IgG (Sigma) was used as a secondary antibody and visualization of immunoreactive bands was performed using the ECL detection system (Amersham).
Results
Production and characterization of the rHDL I taxol complexes.
Recombinant HDL complexes, containing taxol (rHDL/TX) were prepared and characterized as follows. Table I shows the composition of the taxol containing rHDL complexes. The molecular weight of these rHDL/TX complexes (187,000) was established by gel chromatography as described under Materials and Methods. No loss of radioactivity was observed when a ^''C-taxol/rHDL preparation was rechromatographed on the same column, indicating that the rHDL preparation was stable and free from taxol leakage during processing. The molecular weight of the isolated rHDL appears somewhat large (187,000) for the amount of protein being present in the complex (~ 70% by weight). The 3 moles of taxol per mole probably represents underloading of the rHDL/TX particles, as there is significant additional space in the core compartment, occupied by cholesteryl oleate (4% by weight).
The effectiveness of the rHDL ITX complex against cancer cells.
The killing potential of the rHDL / drug complexes against tumor cells was assessed using the sulforhodamine B dye assay. Figure 1 shows the survival of PC-3 cells in the presence of taxol and rHDL/TX, respectively. The concentration of the drug was selected based on the studies of Liebmann et al (27) . Similar studies were conducted with DUl 45, MCF7 and OVl 063 cell lines with essentially identical findings to those shown in Figure I . These data show that the rHDL/TX complex is as efficient as TX in killing cancer cells even though the drug is apparently encapsulated by the HDL surface components.
The data in Table II show the uptake of HDL core components ^H-cholesteryl oleate and taxol from rHDL by an ovarian granulosa cell line (HGL5) and by a series of cancer cells. The ovarian HGL5 cell line was used as the control in these studies to compare the ability of cancer cells to incorporate HDL core components to that of the assumed normal physiological target (20) (21) . The data show that all cancer cells were able to efficiently incorporate cholesteryl esters from rHDL (>65% of the model cell line). The correlation (r=0.88) between the efficiency of cholesteryl ester and taxol uptake by a variety of malignant cells suggest that cancer cells express an HDL receptor, perhaps of the SRB-1 type, that allows the selective uptake of core components from HDL. Figure 2 shows the immunoblots of cell extracts obtained with an SRB-1 antibody. Here the reactivity of the control ovarian cell line (HGL5) was compared with those of a number of cancer cells and a fibroblast cell line. The data show significant immunoreactivity of all cancer cells, especially when compared to normal cells (fibroblasts) that are not known to express this receptor (28) . Finally the specificity of the core component uptake from rHDL was examined by assessing the competition between ^H-cholesteryl oleate labeled and unlabeled rHDL preparations. The data for two cancer cell lines show ( Figure  3 ) that the unlabeled rHDL suppressed the uptake of the labeled cholesteryl ester to a larger extent in the cancer cells compared to the HGL5 ovarian granulosa cell line. These data suggest that the uptake of rHDL core components is at least as specific (mediated by the SRB-1 type receptors ) as for ovarian tissue.
Discussion
Although improvement of cancer chemotherapy by the use of delivery vehicles has been impressive over the last several decades (4, 5) , important challenges, including toxicity of therapeutic agents and drug resistance have been encountered with several types of cancer. We undertook the study of rHDL complexes as potential delivery vehicles for chemotherapeutic agents because they appeared to have desirable properties as drug transporters, due to their size and the receptor mediated uptake of HDL core components (6, 18, 19) . The latter feature could be particularly important as the rapidly dividing cancer cells are likely to have increased cholesterol requirements for membrane biogenesis. In fact, earlier studies have shown that the proliferation of adenocarcinoma cells (20) and breast cancer cells (21) was dependent on the uptake of HDL or HDL components. More recently, at least one breast cancer cell line was shown to express active HDL receptors (29) . Based on these findings, combined with reports in the literature (17) (18) (19) , it is clear that HDL type particles may serve as highly efficient delivery vehicles of anticancer agents. Because of the relatively low levels of expression of these receptors in most peripheral tissues (23) , it is likely that the drugs delivered via HDL type vehicles could have reduced toxic side effects compared to the free drug.
The application of rHDL particles as delivery vehicles for cancer chemotherapeutic agents may be advantageous for several reasons. Poor water solubility is a common feature of many pharmaceutical preparations including several chemotherapeutic agents (29, 30) . A number of recent efforts have been reported to overcome this problem and to reduce the toxicity of the intravenously administered taxol preparations (31, 32) . The rHDL/drug preparations may be particularly effective in this regard as the core components of HDL are normally made up of highly water insoluble compounds (triglycerides and cholesteryl esters). Concerning the effectiveness of taxol and other chemotherapeutic agents, the lack of tumor selectivity is another serious concern. The structure of rHDL allows for the alteration of lipid and protein composition and the covalent attachment of potential targeting vehicles to augment the selectivity of specific agents used in cancer chemotherapy.
Drug resistance of specific tumor cell lines is an another major concern during cancer chemotherapy. In addition to the known drug resistance tumors, certain malignant cells can develop resistance to a particular agent during chemotherapy. The ability of tumors to become resistant to chemotherapy has been linked to specific plasma membrane components (33) , including the transmembrane P-glycoprotein (34) . Because the rHDL preparation is able to interact with specific cell surface receptors (28) and deliver its core components to the interior of the cells without endocytosis, this mechanism may be successful for delivering chemotherapeutic agents without inducing drug resistance.
In summary, we have prepared recombinant high density lipoprotein complexes (rHDL) that contain defined quantities of taxol. We have shown for the first time that the drug incorporated into the rHDL particles is efficiently taken up by several cancer cells presumably via a receptor mediated (SR-Bl type) mechanism. This drug delivery system may be effective in overcoming the poor solubility of many pharmaceutical preparations, increase the selectivity of anticancer drugs and possibly reduce the drug resistance against certain agents, encountered during chemotherapy.
